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Purpose
To describe a possible new autoinflammatory syndrome
in a patient with hyperzincemia and hypercalprotectine-
mia with significant improvement upon initiation of
anakinra.
Methods
We describe a patient initially evaluated at 10 months of
age for gross developmental delay, failure to thrive, sple-
nomegaly, and microcytic anemia. Physical exam was sig-
nificant for weight <3rd percentile, splenomegaly (down
5cm), and head lag. Initial laboratories revealed microcy-
tic anemia (hemoglobin 8.7 g/dL); elevated platelets 499
K/uL, C-reactive protein 23.2 mg/dL (<0.2) and erythro-
cyte sedimentation rate 120 mm/h (0-10). Radiographs
showed Erlenmeyer flask deformities of the femurs.
Workup for lysosomal storage disorders, oncologic pro-
cesses, and infections were negative. Genetic testing of
known mutations in FAS, CIAS1, ELA2, LPIN2, MVK,
PSTPIP1, and TNFRSF1A were negative. Immunoglobu-
lins were elevated with normal T and B cells. On further
workup for failure to thrive, a plasma zinc level was
found elevated at 532 mcg/dL (60-120). Due to his persis-
tently inflamed state, there was concern for hyperzince-
mia related to hypercalprotectinemia. Calprotectin level,
measured by enzyme-linked immunosorbent assay, was
elevated: 428,300 ng/mL (<420). On the basis of these
findings the diagnosis of hyperzincemia associated with
hypercalprotectinemia was made (OMIM 194470). Addi-
tionally, the patient’s workup has revealed the following
mutations with unknown clinical significance: a
heterozygous variant in the MEFV gene (T577A), a hemi-
zygous duplication of exons 61-79 of the dystrophin gene
(CPK normal), and a maternally inherited microduplica-
tion at Xp21.2. Colchicine was started due to the MEFV
gene mutation with little to no improvement. Based on
calprotectin’s role in inflammation, and possible link to
IL-1, anakinra was initiated.
Results
Four weeks after initiation of anakinra, our patient’s
splenomegaly resolved, and inflammatory markers
decreased significantly with improvement in his anemia.
Conclusion
Approximately 8 patients with the diagnosis of hyperzince-
mia and hypercalprotectinemia have been described in the
literature thus far, with the specific genetic cause still
unknown. Consistent clinical findings are hepatospleno-
megaly, anemia, elevated inflammatory markers, as well as
characteristic elevations of serum zinc and calprotectin.
Treatments have included corticosteroids and calcineurin
inhibitors with little or no sustained benefit. We initiated
anakinra due to the role of calprotectin in the inflamma-
tory response. Calprotectin, a complex of S100A8 and
S100A9 proteins, is in the family of calcium-binding pro-
teins expressed by activated neutrophils and monocytes. It
is unique in that it contains zinc-binding domains and
leads to dysregulation of zinc levels when elevated. It is
believed to be involved in antimicrobial activities and has
a regulatory role in inflammatory reactions. Pro-inflamma-
tory cytokines such as IL-1 have been shown to increase
calprotectin levels. This is the first case report to show the
use of an IL-1 inhibitor in a patient with hyperzincemia
and hypercalprotectinemia.
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